• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

    10/8/25 8:00:00 AM ET
    $HTFL
    $INSP
    $LUNG
    $NARI
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email

    -- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth.

    -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care.

    Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than 20,000 patients treated to date with the CVAC System, further establishing the technology as a new standard in kidney stone care.

    Mead brings four decades of medical device operating and investing experience to the Calyxo Board. He currently serves on the Board of Directors of Inspire Medical Systems (NYSE:INSP), Pulmonx (NASDAQ:LUNG), and several commercial-stage private companies. He was a board member of Intersect ENT (NASDAQ:ENT) prior to its acquisition by Medtronic in 2021, and of Inari Medical (NASDAQ:NARI) prior to Stryker's acquisition of the company earlier this year. Other past board appointments include Teladoc Health (NYSE:TDOC). From 2019 to 2021, he was President and CEO of HeartFlow (NASDAQ:HTFL). From 2016 to 2019, he was President and CEO of BVI. Prior to that, he was a Life Science Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, and served in a series of general management roles of increasing responsibility at Guidant.

    "Calyxo is at an exciting inflection point. The company's rapid growth reflects strong physician confidence and a clear need for innovation in kidney stone care. I'm inspired by the team's commitment to advancing patient outcomes and look forward to helping guide this next chapter of growth as the company continues to scale," said Mead.

    "Dana will be an asset to our board. We value his extensive and broad experience across public and private medtech companies of all sizes as we continue to experience positive momentum and growing adoption of the CVAC System," said Joe Catanese, CEO of Calyxo. "Reaching the significant milestone of 20,000 patients treated shows that more physicians are embracing the SURE procedure with the CVAC System, which is designed to achieve greater kidney stone clearance, and marks an important inflection point in Calyxo's growth story."

    Data presented last month at the 42nd World Congress of Endourology and Uro-Technology (WCET) in Phoenix, Ariz. showed the second-generation CVAC System is safe and effective at removing stones, with a mean stone clearance from 94-96%.1 Two-year data from the landmark ASPIRE study showed treatment with SURE using the company's CVAC System resulted in 73% fewer healthcare consumption events (such as emergency room visits, hospitalizations or retreatment*) compared to standard ureteroscopy (URS).2 The study demonstrated residual stone volume was the only significant predictor of post-procedure healthcare consumption events, besides age. This growing body of evidence supporting the safety and effectiveness of the CVAC System is encouraging more urologists to adopt the technology in their practices.

    "The SURE procedure using the second-generation CVAC System has changed the way I care for patients with kidney stones. Now I can achieve greater stone clearance with fewer complications and follow-up interventions. For patients with moderate to large stone burden, the SURE procedure can achieve this less invasively than other procedures. For patients, that means faster recoveries, fewer emergency department visits, less need for a repeat procedure, and less invasive surgical techniques," said Michelle Jo Semins, MD of West Virginia University Medicine. "The CVAC System has become an invaluable part of my treatment approach. Calyxo's commitment to innovation gives physicians like me the confidence that we are providing the best possible care today -- and helping define where kidney stone treatment is headed. This is one of the biggest advancements in surgical stone treatment in decades."

    References:

    1. Eisner et al. MP16: 17 Prospective Evaluation of Steerable Ureteroscopic Renal Evacuation with the Second-Generation CVAC® Aspiration System: Findings from the CLEARANCE Study. Conference Presentation, WCET 2025.

    2. Stern et al. MP16: 01 Steerable ureteroscopic renal evacuation reduces the risk of healthcare consumption events at 2 years compared to standard ureteroscopy (URS). Conference Presentation, WCET 2025.

    * Limited to retreatments likely due to residual stones at the end of the procedure.

    About Kidney Stones

    According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).

    About the CVAC System

    The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.

    About Calyxo, Inc.

    Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.

    "CVAC" and "Calyxo" are registered trademarks of Calyxo, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251008062288/en/

    Alyssa Paldo

    [email protected]

    M: +1 847 791 8085

    Get the next $HTFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL
    $INSP
    $LUNG
    $NARI

    CompanyDatePrice TargetRatingAnalyst
    Inspire Medical Systems Inc.
    $INSP
    9/22/2025$89.00Buy → Neutral
    UBS
    Inspire Medical Systems Inc.
    $INSP
    9/2/2025$150.00Outperform
    Evercore ISI
    Heartflow Inc.
    $HTFL
    9/2/2025$36.00Overweight
    Analyst
    Heartflow Inc.
    $HTFL
    9/2/2025$38.00Overweight
    Piper Sandler
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Buy
    Stifel
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Buy
    Canaccord Genuity
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    Inspire Medical Systems Inc.
    $INSP
    8/5/2025$125.00Buy → Hold
    Truist
    More analyst ratings

    $HTFL
    $INSP
    $LUNG
    $NARI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Mckinley Thomas bought $30,756 worth of shares (4,000 units at $7.69), increasing direct ownership by 11% to 39,077 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    9/13/24 5:14:02 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Catapano Joseph Ronald converted options into 8,333 shares and sold $23,434 worth of shares (2,972 units at $7.89) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    10/3/25 4:05:34 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Director Evans Jason Eric converted options into 1,016 shares, increasing direct ownership by 14% to 8,129 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    9/22/25 4:14:09 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    CHIEF EXECUTIVE OFFICER Divita Charles Iii converted options into 39,160 shares and sold $127,435 worth of shares (16,787 units at $7.59), increasing direct ownership by 14% to 179,014 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    9/11/25 4:04:10 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by UBS with a new price target

    UBS downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $89.00

    9/22/25 8:12:43 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Inspire Medical Systems with a new price target

    Evercore ISI initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $150.00

    9/2/25 8:38:06 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.

    SCHEDULE 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/7/25 3:49:26 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.

    SCHEDULE 13G - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/6/25 5:43:14 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Pulmonx Corporation

    S-3 - Pulmonx Corp (0001127537) (Filer)

    9/26/25 5:19:02 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

    -- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth. -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care. Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than

    10/8/25 8:00:00 AM ET
    $HTFL
    $INSP
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Nursing Services

    Inspire Medical Systems, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025

    MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi

    10/6/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

    MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna across all of its lines of bu

    9/22/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    $HTFL
    $INSP
    $LUNG
    $NARI
    Financials

    Live finance-specific insights

    View All

    Inspire Medical Systems, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025

    MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi

    10/6/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Teladoc Health Acquires Telecare, Expanding Access to Specialist and Allied Health Care for Australians in Public and Private Health

    MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector. With over 300 virtual specialists in over 30 specialties, supporting both GP-referred appointments as well as providing virtual care services to public hospitals across Australia, Telecare helps reduce patient wait times and increases access to speciality care in underserved areas. Teladoc Health is the global

    8/14/25 5:00:10 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last yearAchieved gross margin of 84.0% in the second quarter of 2025Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 millionLoss per share was $0.12 in the second quarter of

    8/4/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care